Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. That's good news, but investors are well ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Eli Lilly (NYSE: LLY) wasn't the first to market with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs have proven more effective than competing products. That's ...

Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity ...

Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north of $1,200. The company experienced tremendous growth ...

Over the past five years at the U.S.-Mexico border, the Rev. Brian Strassburger has gone from ministering to throngs of asylum-seekers in overcrowded shelters to celebrating Mass with detained and ...

SHANGHAI, March 11 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to invest $3 billion in China over the next decade, which will help build production capacity for its experimental ‌type-2 ...

Announcing the submission of a marketing application for its experimental weight loss drug, orforglipron, in China, Eli Lilly (LLY) said on Wednesday that it plans to invest $3B in the country over ...

ALLENTOWN, Pa. - News of multi-national pharmaceutical giant Eli Lilly's move into the Lehigh Valley continues to reverberate. This is especially true for Lehigh Carbon Community College. The school ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

INDIANAPOLIS, Ind. - Less than a week after announcing a major investment in the Lehigh Valley, drugmaker Eli Lilly is predicting a very healthy balance sheet for 2026. On Wednesday morning, the ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of 2024. Now, the momentum has dissipated, and most companies are bracing for ...